Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3962681 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY3962681 (SAD) | EXPERIMENTAL | Single ascending dose of LY3962681 administered intrathecally (IT) to healthy volunteers. |
| Placebo (SAD) | PLACEBO_COMPARATOR | Single ascending dose of placebo (aCSF) administered intrathecally (IT) to healthy volunteers. |
| LY3962681 (MAD) | EXPERIMENTAL | Multiple ascending doses of LY3962681 administered IT to participants with Parkinson's disease. |
| Placebo (MAD) | PLACEBO_COMPARATOR | Multiple ascending doses of placebo (aCSF) administered IT to participants with Parkinson's disease. |
| Name | Type | Description |
|---|---|---|
| LY3962681 | DRUG | IT injection |
| Placebo (aCSF) | OTHER | IT injection |
Inclusion Criteria: * Participant is overtly healthy as determined by medical evaluation. Rescreening is allowed in this study. * A Montreal Cognitive Assessment score greater than or equal to 24. MAD study only * Stable use of background medications at least 8 weeks prior to IP administration, i...
LY3962681 is an investigational small molecule being developed for the treatment of Parkinson's Disease. It is currently in Phase 1 clinical development, with a trial enrolling healthy volunteers and patients with Parkinson's Disease to evaluate its safety and tolerability.
LY3962681 is a small molecule being studied for Parkinson's Disease. Its specific molecular target has not been disclosed in available clinical trial information. The ongoing Phase 1 trial is designed to assess the drug's safety, tolerability, and pharmacokinetics in healthy volunteers and Parkinson's patients.
LY3962681 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the stock exchange under the ticker symbol LLY. The company is conducting a Phase 1 clinical trial to evaluate the drug in healthy volunteers and patients with Parkinson's Disease.
LY3962681 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The Phase 1 trial is currently recruiting participants to study the drug's safety and how it is processed by the body in healthy volunteers and Parkinson's Disease patients.
LY3962681 is being studied in a Phase 1 clinical trial registered as NCT06565195. This randomized, double-blind, controlled trial is recruiting 124 participants across the United States, Germany, Japan, Netherlands, and United Kingdom. The study includes healthy volunteers aged 30 years and older and patients with Parkinson's Disease.